US EditionPfizer sues to stop rival bid for drugmaker Metsera by Denmark’s Novo Nordisk
Pfizer alleges Novo Nordisk's $9 billion bid for Metsera aims to suppress competition and faces regulatory hurdles, challenging Pfizer's $5 billion offer for obesity and diabetes treatments.
- On Friday, New York-based Pfizer sued Metsera Inc. and Denmark's Novo Nordisk to block a rival bid Novo announced Thursday, defending its nearly $5 billion offer.
- Developing oral and injectable candidates, Metsera Inc. targets obesity and diabetes fields and said Novo Nordisk's $9 billion offer appeared superior to Pfizer's September bid.
- Pfizer argues Novo Nordisk's bid is "an illegal attempt by a company with a dominant market position to suppress competition," noting Novo sells Wegovy and Ozempic and faces significant regulatory risk.
- Novo said it planned to buy Metsera Inc. in a deal worth up to $9 billion, and Metsera said the offer appeared superior to Pfizer's September bid.
- Neither Novo Nordisk nor Metsera Inc. responded to requests for comment from The Associated Press after Novo announced its bid Thursday, sparking legal and market disputes.
66 Articles
66 Articles
With an aggressive counter-bid, Novo Nordisk is challenging pharmaceutical giant Pfizer's acquisition of Metsera and signaling a strategic shift in the US market, according to the author of a book about Novo.
Buffalo News
Metsera Issues Statement in Response to Litigation
NEW YORK, Oct. 31, 2025 /PRNewswire/ -- Metsera, Inc. (NASDAQ: MTSR) ("Metsera" or the "Company") today issued the following statement in response to litigation filed against the Company by Pfizer:
Pfizer sues to stop rival bid for drugmaker Metsera by Denmark’s Novo Nordisk
Pfizer is suing over some unsolicited competition in its nearly $5 billion bid to buy the drugmaker Metsera. New York-based Pfizer said Friday after markets closed that it was suing Metsera and a third drugmaker, Denmark’s Novo Nordisk, over a bid for Metsera that Novo announced Thursday. Novo said it planned to buy Metsera in…
Pfizer files lawsuit to block Novo Nordisk's bid for Metsera
Pfizer sues obesity drugmakers
Pfizer has filed a lawsuit in Delaware against Metsera and Novo Nordisk, seeking to block Novo’s US$8.5 billion takeover bid for the U.S. obesity drug developer, which Pfizer claims breaches its existing merger agreement. The pharma giant wants a court order preventing Metsera from terminating their deal and insists the company’s shareholder vote proceed on 13 November. Pfizer recently secured early antitrust clearance for its own US$7.3 billion…
Coverage Details
Bias Distribution
- 55% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
